BAB VI SIMPULAN DAN SARAN
6.2. Saran
1. Perlu dikembangkan penelitian dengan menggunakan populasi yang beragam dari segi usia dan juga status demografik serta mengembangkan penilaian terhadap ekspresi hormonal lain yang dapat menjadi pertimbangan penanganan pada pasien dengan kanker payudara.
2. Perlu dilakukan penelitian lebih lanjut untuk menilai hubungan dengan grading histopatologi.
3. Perlu dilakukan penelitian lanjutan dengan menggunakan jumlah sampel yang lebih besar dan variabel yang beragam untuk mengkonfirmasi kesimpulan dari penelitian ini.
4. Sebagai bahan referensi untuk penelitian selanjutnya mengenai perbedaan signifikan pada ekspresi IGF1R menurut subtipe kanker payudara pada wanita usia sangat muda.
5. Perlu dikembangkan untuk evaluasi sebagai predictor kemoterapi.
DAFTAR PUSTAKA
Adams S, Gray RJ, Demaria S, et al. 2014. Prognostic value of tumor-infiltrating lymphocites in triple negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin. Oncol 2014;32:2959–67.
Akarolo-Anthony SN, Ogundiran TO, Adebamowo WF. 2010. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 12: S8.
Alison E. Obr, Sushil Kumar, Yun-Juan Chang, Joseph J. Bulatowicz, Betsy J.
Barnes, Raymond B. Birge, et al. Insulin-like growth factor receptor signaling in breast tumor epithelium protects cells from endoplasmic reticulum stress and regulates the tumor microenvironment. Breast Cancer Research (2018) 20:138. https://doi.org/10.1186/s13058-018-1063-2
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al.
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26(20):3324–30
Assi HA, Khoury KE. 2013. Epidemiology and Prognosis of Breast Cancer in Young Women. Bioscience Publishing Company. 5(S1): S2-S8.
Betty, Laksmi LI, Siregar KB, 2017. Pre-menopausal Triple-Negative Breast Cancer at HAM Hospital Medan.
Boyle P, 2012. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. DOI:10.1093/annonc/mds187.
Burhanuddin Ramlawati. Analysis Of Pi3KCA Mutation Gene And Level Of Igf-1 In Obese And Non Obese Breast Cancer Patients.20Igf-14. Makasar: FK UNHAS.
Cancello G, et al.2013. Pathological features and survival outcomes of very young patients with early breast cancer: how much is „very young?‟. Breast.
22:1046-1051.
Carlson, Robert H. IGF-1R Biomarker Points to New Target in Triple-Negative Breast Cancer, Oncology Times: November 25, 2010 - Volume 32 - Issue 22 - p 30-31 doi: 10.1097/01.COT.0000391434.50497.2a
Carvalho FM, Bacchi LM, Santos PP, Bacchi CE. Triple-negative breast carcinomas are a heterogeneous entity that differs between young and old patients. Clinics (Sao Paulo) 2010;65:1033–6.
Christopoulos P, et all. The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer Journal. 2015; 14:43
Chu E, et al. Cancer, Principles and Practice of Oncology 7th ed Philadelphia.
Lippincott William and Wilkins. USA 295-306
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thurlimann B, Senn HJ. 2015.Tailoring Therapies - Improving the Management of Early Breast Cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology Advance.
Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 2002;13(2):273–9.
Danijela Batinić-Škipina, Radmil Marić, Ljiljana Tadić-Latinović, Dražan Erić, and Lalović Nenad. Immunohistochemical Evaluation of Insulin-like Growth Factor Receptor 1 in Breast Cancer. Srp Arh Celok Lek 2017│Online First September 29, 2017, DOI: https://doi.org/10.2298/SARH170707177B.
De Beer JC, Liebenberg L. Does cancer risk increase with HbA1c, independent of diabetes? Br J Cancer. 2014;110(9):2361e2368.
Dieci MV, Mathieu MC, Guarneri V, Conte P, Delaloge S, Andre F, et al.
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015 Aug;
26(8):1698-704.
Dupont J, Le Roith D. Insulin-like growth factor 1 and oestradiol promote cell proliferation of MCF-7 breast cancer cells: new insights into their synergistic effects. Mol Pathol. 2001;54(3):149e154.
Dyanti GAR, Suariyani NLP. 2016. Faktor-Faktor Keterlambatan Penderita Kanker Payudara dalam Melakukan Pemeriksaan Awal ke Pelayanan Kesehatan. Jurnal Kesehatan Masyarakat, 11(2).
Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A. Molecular biology in breast cancer: intrinsic subtypes and signaling pathways. Cancer Treat Rev (2012) 38: 698–707. doi:10.1016/j.ctrv.2011.11.005
Fernandopulle SM, Cher-Siangang P, Tan PH. Breast carcinoma in women 35 years and younger: a pathological study. Pathology 2006;38(3):219–22.
Fredholm H, Eaker S, Frisell J, et al, 2009. Breast cancer in young women: Poor survival despite intensive treatment. PlosOne. 4(11):1-9.
Gaben A, Sabbah M, Redeuilh G, Bedin M and Mester J: Ligand free estrogen receptor activity complements IGF1R to induce the proliferation of the MCF-7 breast cancer cells. BMC Cancer 12: 291, 2012. PMID: 22MCF-799881. DOI:
59
Gabriel CA, Domchek SM, 2010. Breast Cancer in Young Women. Breast Cancer Research. 12: 2126.
Gallicchio L, MacDonald R, Helzlsouer KJ (2013). Insulin-like growth factor 1 and musculoskeletal pain among breast cancer patients on aromatase inhibitor therapy and women without a history of cancer. J Cancer Res Clin Oncol 139(5):837–43. Epub 2013 Feb 14.
Giannis Mountzios, Dimitra Aivazi, Ioannis Kostopoulos, Helen P. Kourea, George Kouvatseas, Eleni Timotheado, et al. Differential Expression of the Insulin-Like Growth Factor Receptor among Early Breast Cancer Subtypes.
Plos One, March 2014, Volume 9, Issue 3, e91407.
Gingras I, Azim HA, Ignatiadis M, Sotiriou C. 2015. Immunology and Breast Cancer: Toward a New Way of Understanding Breast Cancer and Developing Novel Therapeutic Strategies. Clinical Advances in Hematology
& Oncology: 13.
Gnerlich JL, Williams RT, Yao K, Jaskowiak N, Kulkarni SA. Utilization of radiotherapy for malignant phyllodes tumors: analysis of the National Cancer Data Base, 1998-2009. Ann Surg Oncol. 2014 Apr;21(4):1222-30.
Hartaningsih NMD, Sudarsa IW, 2013. Kanker Payudara Pada Wanita Usia Muda di Bagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2002–2012. Garuda. 1-14.
Hartaningsih D, Sudarsa. 2014. Kanker Payudara Pada Pasien Wanita Usia Muda di Bagian Bedah Onkologi Rumah Sakit Umum Pusat Sanglah Denpasar Tahun 2002- 2012. Jurnal Medika Udayana, 3 (6).
Keegan THM, et al. 2012. Occurance of Breast Cancer Subtypes in Adolescent and Young Adult Woman. Breast Cancer Research.14 (2).
Keegan, TH, DeRouen MC, Press DJ, Kurian AW, Clarke CA, 2013. Impact of Breast Cancer Subtypes on 3-Year Survival among Adolescent and Young Adult Women. Breast Cancer Research. 15: R95.
Lee HB, Han W, 2014. Unique Features of Young Age Breast Cancer and Its Management. Journal of Breast Cancer. 17(4): 301-7.
Lian W, Fu F, Lin Y, Lu M, Chen B, Yang P, Zeng B, Huang M, Wang C (2017) The impact of young age for prognosis by subtype in women with early breast cancer. Sci Rep 7(1):11625 10.1038/s41598-017-10414-x [PubMed:
28912475]
Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer.
Endocrine Related Cancer 2006 Jun; 13(2):279-92
McDonaldM, Hertz RP, Lowenthal SWP, 2008.The Burden of Cancer in Asia.
PFIZER Medical Division.
Nahta R. Deciphering the role of insulin-like growth factor-I receptor in trastuzumab resistance. Chemother Res Pract 2012;2012:648965.
Nasution TBS, 2018. Angka Kejadian dan Karakteristik Kanker Payudara pada Wanita Usia Sangat Muda ≤ 35 Tahun Di RSUP H. Adam Malik, USU.
NCCN. (2012). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Breast Cancer, National Comprehensive Cancer Network, Inc., United States of America.
Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, et al. (2004).
Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival:
potential for intervention with 17-allylamino geldanamycin. Cancer Res 64(1):286–91.
Noura Alkhayyal, Iman Talaat, Arya Vinodnadat, Azzam Maghazachi, Salah Abusnana, Kari Syrjänen, et al. Correlation of Insulin-like Growth Factor 1 Receptor Expression With Different Molecular Subtypes of Breast Cancer in the UAE. Anticancer Research 40: 1555-1561 (2020) doi:10.21873/anticanres.14102.
Panagiotis F Christopoulos, Pavlos Msaouel, and Michael Koutsilieris. The role of the insulin-like growth factor-1 system in breast cancer. Molecular Cancer (2015) 14:43. DOI 10.1186/s12943-015-0291-7.
Partridge AH, Aron G, Gelber RD, 2009. Breast Cancer in Young Women.
Disease of the Breast Fourth Edition. 92: 1073-1080.
PERABOI.Panduan Penatalaksanaan Kanker Payudara. Jakarta, Hal 50, Edisi 2015
Piccart M, Wood WC, Hung CM, Solin LJ, Cardoso F, 2006. Breast Cancer Management and Molecular Medicine: Towards Tailored Approaches. 119-213. Springer. New York.
Reyna C, Lee MC, 2014. Breast cancer in young women: special considerations in multidisciplinary care. Journal of Multidisciplinary Healthcare. 7: 419-429.
Rinat Yerushalmi, Karen A. Gelmon, Samuel Leung, Dongxia Gao, Maggie Cheang, Michael Pollak, et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat (2012) 132:131–142. DOI 10.1007/s10549-011-1529-8.
61
Sahitya K. Denduluri, Olumuyiwa Idowu, Zhongliang Wang, Zhan Liao, Zhengjian Yan, Maryam K. Mohammed, et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes & Diseases (2015) 2, 13-25.
Shunchao Yan, Xin Jiao, Kai Li, Wusheng Li, and Huawei Zou. The impact of IGF-1R expression on the outcomes of patients with breast cancer: a meta-analysis. OncoTargets and Therapy 2015:8 279–287.
Siregar KB, Manuaba TW, Lubis MND, Sembiring RJ, 2017. Caspase 3 as Prognostic Marker for Triple Negative Breast Cancer Chemotherapy. Asian J Pharm Clin Res, Vol 10, Issue 11, 2017, 304-307.
Sobri FB, Azhar Y, Wibisana IGNG, Rachman A, 2017. Manajemen Terkini Kanker Payudara. Edisi ke-1. Media Aesculapius. Jakarta.
Solinas C, Carbognin L, De Silva P, Criscitiello C, Lambertini M, 2017. Tumor-infiltrating lymphocytes in breast cancer according to tumorsubtype: Current state of the art. The Breast 35 (2017) 142-150. DOI:
10.1016/j.breast.2017.07.005
Stanton SE, Adams S, Disis ML. 2016. Variations in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer: a systematic review.
JAMA Oncol. 2016; 23.
Susan M. Farabaugh, David N. Boone, and Adrian V. Lee. Role of IGF1R in breast cancer subtypes, stemness, and lineage differentiation. 2015. Front.
Endocrinol. 6:59. doi: 10.3389/fendo.2015.00059.
The St. Gallen International Expert Consensus Conferenc, 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer. Annals of Oncology 28: 1700–1712, 2017 doi:10.1093/annonc/mdx308
Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, et al, 2013. Breast Cancer in Young Women in Latin America: An Unmet, Growing Burden. The Oncologist. 18:1298-130
Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, et al. Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes. Breast Cancer Res Treat 2012;132:131-42
Yersal O, Barutca S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J Clin Oncol. 2014;5:412–24
YingM, GuanX, Liao Z, Wei Q. Insulin-like growth factor 1 receptor targeted therapy for non small cell lung cancer: A mini review. AmJTransl Res.2009;1(2):101-14.
Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst. 2000;92:1472–89.
Zaha DC. 2014. Significance of Immunohistochemistry in Breast Cancer. World J Clin Oncol 2014;5(3):382-92.
63